Global Pneumothorax Infection Treatment Market, By Type (Primary Spontaneous Pneumothorax, Secondary Spontaneous Pneumothorax, Latrogenic Pneumothorax, Injury-related Pneumothorax, Catamenial Pneumothorax), Treatment (Medication, Needle Aspiration, Chemical Pleurodesis, Chest Tube Drainage, Surgery, Others), Diagnosis (Chest X-ray, Computerized Tomography (CT) Scan, Ultrasound, Physical Examination, Others), Symptoms (Chest Pain, Tachypnoea, Dyspnoea, Dry cough, Subcutaneous emphysema, Signs of respiratory distress, Fatigue, Hypotension, Tachycardia, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Injectable, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Pneumothorax Infection Treatment Market Analysis and Size
The rise in the prevalence of pneumothorax infection and rising healthcare expenditure are the major factors influencing the market growth rate. Furthermore, growing government funding and rising initiatives by public and private organisations to spread awareness about the disease and its available treatment are the factors that will expand the pneumothorax infection treatment market. Other factors including growing incidences of asthma, lung cancer, tuberculosis, cystic fibrosis and bacterial pneumonia and increase in the consumption of alcohol and smoking tobacco will positively impact the market growth rate.
Data Bridge Market Research analyses that the pneumothorax infection treatment market which was USD 19.18 billion in 2022, would rocket up to USD 53.35 billion by 2030, and is expected to undergo a CAGR of 5.30% during the forecast period. This indicates that the market value. “infectious diseases” dominates the application segment of the pneumothorax infection treatment market owing to an increase in the number of infectious diseases, such as COVID-19. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pneumothorax Infection Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Primary Spontaneous Pneumothorax, Secondary Spontaneous Pneumothorax, Latrogenic Pneumothorax, Injury-related Pneumothorax, Catamenial Pneumothorax), Treatment (Medication, Needle Aspiration, Chemical Pleurodesis, Chest Tube Drainage, Surgery, Others), Diagnosis (Chest X-ray, Computerized Tomography (CT) Scan, Ultrasound, Physical Examination, Others), Symptoms (Chest Pain, Tachypnoea, Dyspnoea, Dry cough, Subcutaneous emphysema, Signs of respiratory distress, Fatigue, Hypotension, Tachycardia, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Injectable, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Medtronic (Ireland), Angiotech (Canada), Teleflex Incorporated (U.S.), Abbott (U.S.), Smiths Group plc. (U.K.), ATMOS MedizinTechnik GmbH & Co. KG (Germany), Nobelpharma Co., Ltd (Japan), Vygon (France), Zebra Medical Vision, Inc. (Israel), Allergan (Ireland), Merck Sharp & Dohme Corp. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Eli Lilly and Company (U.S.), among others
|
|
Market Opportunities
|
|
Market Definition
Pneumothorax is also known as collapsed lung. When air gets into the space around your lungs, it's called a pneumothorax (the pleural space). When your chest wall is injured or your lung tissue is torn or ruptured, air can enter the pleural space, upsetting the pressure that keeps your lungs inflated. Lung disease, assisted breathing with a ventilator, injury from a sport or accident, or even variations in air pressure experienced during scuba diving or mountain climbing are all possible causes of ruptured or wounded chest or lung walls. The aetiology of a pneumothorax is sometimes unknown. This condition is characterized by chest pain, tachypnoea, dyspnoea, dry cough, and subcutaneous emphysema, signs of respiratory distress, fatigue, hypotension and tachycardia
Pneumothorax Infection Treatment Market Dynamics
Drivers
- Increasing Incidence of Pneumothorax
The rising incidence of pneumothorax, which can result from various factors such as trauma, surgery, or underlying lung conditions, is a significant driver. As the population grows and ages, the prevalence of conditions leading to pneumothorax is likely to increase, driving the demand for pneumothorax infection treatment
- Advancements in Medical Technology
Advances in medical technology, particularly in minimally invasive surgical techniques and imaging technologies, have improved the diagnosis and treatment of pneumothorax and related infections. These advancements make treatments more effective, less invasive, and reduce recovery times, thus boosting the market
- Increasing Awareness and Early Diagnosis
As awareness about the risks and consequences of pneumothorax and related infections grows, there is a greater emphasis on early diagnosis and treatment. Public health campaigns, medical education, and the integration of healthcare systems contribute to this awareness, driving market growth
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities
Opportunities
- Rising Healthcare Investments
Increasing investments in healthcare infrastructure, particularly in emerging markets, create opportunities for market growth. Expanding healthcare facilities, improving access to medical services, and enhancing the availability of advanced treatments can drive demand for pneumothorax infection treatment
- Telemedicine and Remote Monitoring
The adoption of telemedicine and remote monitoring technologies offers opportunities to provide timely consultations and follow-up care for patients with pneumothorax and related infections. This can improve patient compliance with treatment plans and facilitate early intervention when necessary
Restraints/ Challenges
- Limited Awareness and Diagnosis
Despite efforts to raise awareness, pneumothorax and related infections can still go undiagnosed or misdiagnosed. This limitation in early diagnosis and awareness can restrain market growth as delayed treatment may result in more severe cases
- Stringent Regulatory Requirements
The development and approval of new treatments and medical devices for pneumothorax and associated infections are subject to stringent regulatory requirements. Complying with these regulations can be time-consuming and expensive, which can slow down the introduction of new products into the market
- Diagnostic Challenges
Accurately diagnosing pneumothorax and associated infections can be challenging, especially in cases where symptoms are subtle or when imaging techniques are not readily available. Misdiagnosis or delayed diagnosis can lead to inadequate or delayed treatment
- Treatment Complexity
The treatment of pneumothorax and related infections can be complex, especially in severe cases. Surgical interventions may be required, and these procedures can carry risks and complications. Balancing the need for effective treatment with the potential for adverse events can be a challenge
This pneumothorax infection treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pneumothorax infection treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Global Pneumothorax Infection Treatment Market Scope
The pneumothorax infection treatment market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Primary spontaneous pneumothorax
- Secondary spontaneous pneumothorax
- Latrogenic pneumothorax
- Injury-related pneumothorax
- Catamenial pneumothorax
Treatment
- Medication
- Antibiotics
- Benzodiazepines
- Opiate anesthetics
- Others
- Needle aspiration
- Chemical pleurodesis
- Chest tube drainage
- Surgery
- Others
Diagnosis
- Chest x-ray
- Computerized tomography (ct) scan
- Ultrasound
- Physical examination
- Others
Symptoms
- Chest pain
- Tachypnea
- Dyspnea
- Dry cough
- Subcutaneous emphysema
- Signs of respiratory distress
- Fatigue
- Hypotension
- Tachycardia
- Others
Dosage
- Tablet
- Injection
- Others
Route of Administration
- Oral
- Injectable
- Others
End-users
- Clinic
- Hospital
- Others
Distribution channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
Pneumothorax Infection Treatment Market Regional Analysis/Insights
The pneumothorax infection treatment market is analysed and market size insights and trends are provided by type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the pneumothorax infection treatment market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
North America dominates the pneumothorax infection treatment market due to presence of major key players, high disposable income and well-developed healthcare infrastructure in this region.
Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The pneumothorax infection treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for pneumothorax infection treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the pneumothorax infection treatment market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Pneumothorax Infection Treatment Market Share Analysis
The pneumothorax infection treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pneumothorax infection treatment market
Some of the major players operating in the pneumothorax infection treatment market are:
- Medtronic (Ireland)
- Angiotech (Canada)
- Teleflex Incorporated (U.S.)
- Abbott (U.S.)
- Smiths Group plc. (U.K.)
- ATMOS MedizinTechnik GmbH & Co. KG (Germany)
- Nobelpharma Co., Ltd (Japan)
- Vygon (France)
- Zebra Medical Vision, Inc. (Israel)
- Allergan (Ireland)
- Merck Sharp & Dohme Corp. (U.S.)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Eli Lilly and Company (U.S.)
SKU-